| Alteration of Cadherin 3 Expression and DNA Methylation in Association with Aggressive Renal Cell Carcinoma. | Alteration of Cadherin 3 Expression and DNA Methylation in Association with Aggressive Renal Cell Carcinoma.
Faraj Tabrizi P, Peters I, Schimansky I, Dubrowinskaja N, Reese C, Tezval H, Kuczyk MA, Serth J., Free PMC Article | 12/4/2023 |
| CDH3 is associated with poor prognosis by promoting the malignancy and chemoresistance in oral squamous cell carcinoma. | CDH3 is associated with poor prognosis by promoting the malignancy and chemoresistance in oral squamous cell carcinoma.
Wu T, Xiao Z, Li Y, Jiao Z, Liang X, Zhang Y, Liu H, Yang A. | 11/26/2022 |
| Novel compound heterozygous cadherin 3 mutations in hypotrichosis and juvenile macular dystrophy. | Novel compound heterozygous cadherin 3 mutations in hypotrichosis and juvenile macular dystrophy.
Ren Y, Liu J, Yao D, Hua H, Guo X, Dai H, Dang N, Huang Y, Yu D., Free PMC Article | 10/29/2022 |
| Cadherin-3 is a novel oncogenic biomarker with prognostic value in glioblastoma. | Cadherin-3 is a novel oncogenic biomarker with prognostic value in glioblastoma.
Martins EP, Gonçalves CS, Pojo M, Carvalho R, Ribeiro AS, Miranda-Gonçalves V, Taipa R, Pardal F, Pinto AA, Custódia C, Faria CC, Baltazar F, Sousa N, Paredes J, Costa BM., Free PMC Article | 07/30/2022 |
| Placental-Cadherin, a biomarker for local immune status and poor prognosis among patients with tongue squamous cell carcinoma. | Placental-Cadherin, a biomarker for local immune status and poor prognosis among patients with tongue squamous cell carcinoma.
Wang H, Yu T, Mao L. | 06/11/2022 |
| P-Cadherin Regulates Intestinal Epithelial Cell Migration and Mucosal Repair, but Is Dispensable for Colitis Associated Colon Cancer. | P-Cadherin Regulates Intestinal Epithelial Cell Migration and Mucosal Repair, but Is Dispensable for Colitis Associated Colon Cancer.
Naydenov NG, Lechuga S, Zalavadia A, Mukherjee PK, Gordon IO, Skvasik D, Vidovic P, Huang E, Rieder F, Ivanov AI., Free PMC Article | 05/28/2022 |
| P-Cadherin and WNT5A expression in assessment of lymph node metastasis in oral squamous cell carcinoma. | P-Cadherin and WNT5A expression in assessment of lymph node metastasis in oral squamous cell carcinoma.
Khan W, Haragannavar VC, Rao RS, Prasad K, Sowmya SV, Augustine D, Patil S. | 02/5/2022 |
| Phase I Study of P-cadherin-targeted Radioimmunotherapy with (90)Y-FF-21101 Monoclonal Antibody in Solid Tumors. | Phase I Study of P-cadherin-targeted Radioimmunotherapy with (90)Y-FF-21101 Monoclonal Antibody in Solid Tumors.
Subbiah V, Erwin W, Mawlawi O, McCoy A, Wages D, Wheeler C, Gonzalez-Lepera C, Liu H, Macapinlac H, Meric-Bernstam F, Hong DS, Pant S, Le D, Santos E, Gonzalez J, Roszik J, Suzuki T, Subach RA, Madden T, Johansen M, Nomura F, Satoh H, Matsuura T, Kajita M, Nakamura E, Funase Y, Matsushima S, Ravizzini G. | 11/27/2021 |
| Aberrant Expression of E-cadherin, N-cadherin, and P-cadherin in Clear Cell Renal Cell Carcinoma: Association With Adverse Clinicopathologic Factors and Poor Prognosis. | Aberrant Expression of E-cadherin, N-cadherin, and P-cadherin in Clear Cell Renal Cell Carcinoma: Association With Adverse Clinicopathologic Factors and Poor Prognosis.
Jang NR, Choi JH, Gu MJ. | 11/6/2021 |
| E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements. | E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements.
Christgen M, Bartels S, van Luttikhuizen JL, Bublitz J, Rieger LU, Christgen H, Stark H, Sander B, Lehmann U, Steinemann D, Derksen PWB, Kreipe H., Free PMC Article | 10/16/2021 |
| Integrative Omics Analysis Reveals Soluble Cadherin-3 as a Survival Predictor and an Early Monitoring Marker of EGFR Tyrosine Kinase Inhibitor Therapy in Lung Cancer. | Integrative Omics Analysis Reveals Soluble Cadherin-3 as a Survival Predictor and an Early Monitoring Marker of EGFR Tyrosine Kinase Inhibitor Therapy in Lung Cancer.
Hsiao TF, Wang CL, Wu YC, Feng HP, Chiu YC, Lin HY, Liu KJ, Chang GC, Chien KY, Yu JS, Yu CJ. | 09/18/2021 |
| Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study. | Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
Kayahashi K, Mizumoto Y, Matsuoka A, Obata T, Iwadare J, Nakamura M, Daikoku T, Fujiwara H., Free PMC Article | 05/15/2021 |
| Chloride Intracellular Channel Protein 1 (CLIC1), E-cadherin and P-cadherin Define Distinct Subclasses of HER2, Luminal B and Triple-negative Breast Cancer. | Chloride Intracellular Channel Protein 1 (CLIC1), E-cadherin and P-cadherin Define Distinct Subclasses of HER2, Luminal B and Triple-negative Breast Cancer.
Raica M, Ceausu AR, Cimpean AM, ComŞa Ş, Sarb S. | 02/6/2021 |
| Novel CDH3 variants in Brazilian families with hypotrichosis and juvenile macular dystrophy revealed by exome sequencing. | Novel CDH3 variants in Brazilian families with hypotrichosis and juvenile macular dystrophy revealed by exome sequencing.
Schauren JS, Torres ACMBG, de Almeida RC, Santos PSC, Mulinari-Brenner F, Lima LH, Zago Filho LA, Shiokawa N, Bicalho MDG, Sato MT. | 02/6/2021 |
| P-cadherin induces anoikis-resistance of matrix-detached breast cancer cells by promoting pentose phosphate pathway and decreasing oxidative stress. | P-cadherin induces anoikis-resistance of matrix-detached breast cancer cells by promoting pentose phosphate pathway and decreasing oxidative stress.
Sousa B, Pereira J, Marques R, Grilo LF, Pereira SP, Sardão VA, Schmitt F, Oliveira PJ, Paredes J. | 01/23/2021 |
| Correlating Adaptive Optics Images to Clinical Findings in Juvenile Macular Dystrophy with Hypotrichosis in Siblings with Homozygous CDH3 Pathogenic Variation. | Correlating Adaptive Optics Images to Clinical Findings in Juvenile Macular Dystrophy with Hypotrichosis in Siblings with Homozygous CDH3 Pathogenic Variation.
Nasser F, Kempf M, Kurtenbach A, Stöhr H, Weber BHF, Neuhaus C, Rating P, Zrenner E. | 01/9/2021 |
| Differential Expression of E-Cadherin and P-Cadherin in Breast Cancer Molecular Subtypes. | Differential Expression of E-Cadherin and P-Cadherin in Breast Cancer Molecular Subtypes.
Margan MM, Cimpean AM, Ceausu AR, Raica M. | 10/10/2020 |
| Deletion in CDH3 is associated with Hypotrichosis with juvenile macular dystrophy. | Hypotrichosis with juvenile macular dystrophy: Combination of whole-genome sequencing and genome-wide homozygosity mapping identifies a large deletion in CDH3 initially undetected by whole-exome sequencing-A lesson from next-generation sequencing.
Saeidian AH, Vahidnezhad H, Youssefian L, Sotudeh S, Sargazi M, Zeinali S, Uitto J., Free PMC Article | 07/4/2020 |
| Overexpressed ADAMTS9-AS2 aids in the suppression of esophageal cancer development, which is achieved via inducing CDH3 promoter methylation. | Long noncoding RNA ADAMTS9-AS2 suppresses the progression of esophageal cancer by mediating CDH3 promoter methylation.
Liu D, Wu K, Yang Y, Zhu D, Zhang C, Zhao S. | 04/18/2020 |
| This case shows that a CDH3 mutation besides macula dystrophy can cause widespread cone-rod dystrophy with hypotrichosis without any other pathology besides hypoplastic nails. | Hypotrichosis with cone-rod dystrophy in a patient with cadherin 3 (CDH3) mutation.
Nasser F, Mulahasanovic L, Alkhateeb M, Biskup S, Stingl K, Zrenner E. | 05/18/2019 |
| this study shows that high expression of P-cadherin is significantly associated with poor prognosis in patients with non-small-cell lung cancer | High expression of P-cadherin is significantly associated with poor prognosis in patients with non-small-cell lung cancer.
Imai S, Kobayashi M, Takasaki C, Ishibashi H, Okubo K. | 05/18/2019 |
| trans-suppression of host CDH3 and LOXL4 genes in cultured human intestinal epithelial cells following C. parvum infection involves nuclear delivery of parasite Cdg7_FLc_1000 RNA. | Trans-suppression of host CDH3 and LOXL4 genes during Cryptosporidium parvum infection involves nuclear delivery of parasite Cdg7_FLc_1000 RNA.
Ming Z, Gong AY, Wang Y, Zhang XT, Li M, Li Y, Pang J, Dong S, Strauss-Soukup JK, Chen XM., Free PMC Article | 05/4/2019 |
| The role of P-cadherin in prostate carcinoma could not be determined, but it might be context-dependent. | Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features.
Ferreira C, Lobo J, Antunes L, Lopes P, Jerónimo C, Henrique R. | 04/13/2019 |
| Results show that Cadherin-3 is detected early at the plasma membrane during progression of pancreatic intraepithelial neoplasia 1 (PanIN-1) to pancreatic ductal adenocarcinoma (PDAC). Also, cadherin-3 regulates tumor growth and cell migration. | Cadherin-1 and cadherin-3 cooperation determines the aggressiveness of pancreatic ductal adenocarcinoma.
Siret C, Dobric A, Martirosyan A, Terciolo C, Germain S, Bonier R, Dirami T, Dusetti N, Tomasini R, Rubis M, Garcia S, Iovanna J, Lombardo D, Rigot V, André F., Free PMC Article | 01/26/2019 |
| the evaluation of P-cadherin expression in lymph node metastases is an important predictor of disease outcome in breast cancer axillary lymph node metastases | P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice.
Vieira AF, Dionísio MR, Gomes M, Cameselle-Teijeiro JF, Lacerda M, Amendoeira I, Schmitt F, Paredes J. | 03/10/2018 |